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Report
The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation
Present in Geographically Diverse Populations
The BRCA1 Exon 13 Duplication Screening Group*
Recently, a 6-kb duplication of exon 13, which creates a frameshift in the coding sequence of the BRCA1 gene,
has been described in three unrelated U.S. families of European ancestry and in one Portuguese family. Here, our
goal was to estimate the frequency and geographic diversity of carriers of this duplication. To do this, a collaborative
screening study was set up that involved 39 institutions from 19 countries and included 3,580 unrelated individuals
with a family history of the disease and 934 early-onset breast and/or ovarian cancer cases. A total of 11 additional
families carrying this mutation were identified in Australia (1), Belgium (1), Canada (1), Great Britain (6), and the
United States (2). Haplotyping showed that they are likely to derive from a common ancestor, possibly of northern
British origin. Our results demonstrate that it is strongly advisable, for laboratories carrying out screening either
in English-speaking countries or in countries with historical links with Britain, to include within their BRCA1
screening protocols the polymerase chain reaction–based assay described in this report.
Methods used to screen for mutations in the BRCA1
gene (MIM 113705) focus mainly on genomic DNA,
and, being PCR based, they do not enable the detection
of large DNA rearrangements. This may explain why
only 12 large germline insertions or deletions have been
described (Petrij-Bosch et al. 1997; Puget et al. 1997,
1999a, 1999b; Swensen et al. 1997; Montagna et al.
1999; Rohlfs et al. 2000), compared with ∼400 point
mutations, small insertions, and deletions scattered
across the whole coding sequence and over the splice
junctions (Breast Cancer Information Core). However,
in two independent studies performed on Dutch (Petrij-
Bosch et al. 1997) and U.S. (Puget et al. 1999a) families
with breast and/or ovarian cancer, rearrangements have
been found to represent 36% and 15% of all mutations,
respectively.
Recently, a 6-kb duplication of exon 13, ins6kbEx13,
which creates a frameshift in the coding sequence, has
been identified in the BRCA1 gene (Puget et al. 1999b).
It was initially found in three, apparently unrelated, U.S.
families of European ancestry and in one Portuguese
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family. Haplotype data suggested a common founder for
all these families.
To estimate the frequency and geographic diversity of
carriers of this duplication, which will not be identified
if not specifically sought, a collaborative study was set
up. This involved 39 institutions in which the screening
for ins6kbEx13 was done by PCR (fig. 1) using specific
primers and a positive control. A total of 3,580 unrelated
individuals with a family history of breast and/or ovar-
ian cancer who were from 19 different countries (Aus-
tralia, Austria, Belgium, Canada, Finland, France, Ger-
many, Great Britain, Hungary, Ireland, Israel, Italy, the
Netherlands, Norway, Spain, Sweden, Switzerland, Tur-
key, and the United States) were screened. To be enrolled,
the family histories had to fulfill at least one of the fol-
lowing criteria: (1) at least three cases of female breast
and/or ovarian cancer; (2) at least one case of female
breast cancer and one case of male breast cancer; (3)
one case of female breast cancer diagnosed at age !50
years and one case of ovarian or female breast cancer;
(4) one case of female breast cancer and one case of
ovarian cancer in first-degree relatives; (5) one case of
female breast cancer and one case of female bilateral
breast cancer; or (6) two cases of ovarian cancer. This
heterogeneous sample is representative of the diversity
of patients who attend clinics for individuals at high risk
for cancer. At the time of the analysis, the whole coding
sequence and the splice sites of the BRCA1 and BRCA2
genes had been screened for the presence of mutations
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Figure 1 Schematic representation of BRCA1 exon 13 duplication. The location and orientation of the dup13F (GAT TAT TTC CCC
CCA GGC TA) and dup13R (AGA TCA TTA GCA AGG ACC TGT G) primers are represented, along with the position of the 6-kb duplicated
region and of the 1.1-kb PCR fragment generated with dup13F/R. Blackened boxes denote exons; dotted lines denote intron 12; and broken
lines denote intron 13.
Table 1
BRCA1 Exon 13–Duplication Screening in English-Speaking Countries
COUNTRY
AND TOWN
NO. OF
POSITIVE
FAMLIIES
NO. OF SCREENED FAMILIESa
Total
Breast Cancer
Only
Breast and
Ovarian Cancer
Ovarian Cancer
Only
Australia:
Westmead 1 40 33 7 0
Canada:
Montreal 0 5b 1 4 0
Toronto 1 504 319 174 11
Ireland:
Dublin 0 73 15 50 8
United Kingdom:
Cambridge 0 56 0 15 41
St Andrews 1 150 112 38 0
Leeds 4 44 0 44 0
London 1 278 210 68 0
Sutton 0 94 NC NC NC
United States:
Chapel Hill 0 61 39 21 1
New York 0 92 64 27 1
Philadelphia 1 110 65 45 0
Rochester 1 257 206 51 0
Salt Lake City 0 67 43 24 0
Total 10 1,831 11,107 1568 162
a NC = not communicated.
b No French Canadian or Jewish Ashkenazi families were included.
in 61% and 37%, respectively, of the families; the screen-
ing had not been completed in 31% (BRCA1) and 43%
of them (BRCA2); it had not been attempted in 8%
(BRCA1) and 20% (BRCA2).
From this series of families, 1,831 were recruited and
screened in English-speaking countries, and 10 appar-
ently independent families were found to carry the du-
plication in Australia (1), Canada (1), Great Britain (6),
and the United States (2) (table 1). No duplications were
found in the 1,749 families who were recruited and
screened in non–English-speaking countries (table 2).
Ten of the institutions involved in this project also sought
the presence of the duplication in 934 additional sam-
ples, mainly breast cancer cases selected for an early age
at onset (table 3). One non–English-speaking duplica-
tion carrier was found in this second series: a Belgian
woman with breast cancer diagnosed at age 34 years
whose mother also developed breast cancer. If we also
include the 4 families previously identified (Puget et al.
1999a), a total of 15 apparently unrelated families have
been found to carry ins6kbEx13 (table 4). As seen with
the other recurrent mutations (Tonin et al. 1996), these
15 families display a spectrum of different breast and
ovarian cancer phenotypes.
Haplotype analysis was conducted with seven poly-
morphic short-tandem-repeat markers within or flank-
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Table 2
BRCA1 Exon 13–Duplication Screening in Non–English-Speaking Countries
COUNTRY
AND TOWN
NO. OF
POSITIVE
FAMILIES
NO. OF SCREENED FAMILIES
Total
Breast Cancer
Only
Breast and
Ovarian Cancer
Ovarian Cancer
Only
Austria:
Vienna 0 238 177 52 9
Belgium:
Gent 0 30 26 3 1
Canada:
Quebec 0 45 40 5 0
Finland:
Helsinki 0 161 126 35 0
France:
Clermont-Ferrand 0 36 24 9 3
Lille 0 115 103 5 7
Nantes 0 48 39 8 1
Villejuif 0 70 46 24 0
Paris 0 51 44 7 0
St. Cloud 0 117 96 20 1
Germany:
Dusseldorf 0 45 36 8 1
Heidelberg 0 75 52 22 1
Hungary:
Budapest 0 25 24 1 0
Israel:
Tel Hashomer 0 76 62 14 0
Italy:
Milan 0 48 35 13 0
Padua 0 96 54 33 9
Pisa 0 17 3 14 0
Netherlands:
Leiden 0 30 26 4 0
Utrecht 0 200 168 27 5
Norway:
Oslo 0 19 1 13 5
Spain:
Barcelona 0 85 58 27 0
Madrid 0 76 60 16 0
Sweden:
Lund 0 29 0 20 9
Switzerland:
Geneva 0 8 6 2 0
Turkey:
Ankara 0 9 8 0 1
Total 0 1,749 1,314 382 53
ing the BRCA1 locus and spanning ∼1.9 Mb (from
centromere to telomere, these markers are D17S1185,
D17S1321, D17S1323, D17S1322, D17S855, D17S1326,
and D17S1325; data not shown). In 8 of the 15 families,
a single sample was available; thus, it was not possible
to determine phase. Nevertheless, all exon 13–duplica-
tion carriers had genotypes compatible with their shar-
ing the same haplotype. Because the particular alleles
shared by duplication carriers at D17S1185 and
D17S855 have population frequencies !15%, we can
conclude that this duplication has most likely spread
from a common ancestor. Unfortunately, because of an
insufficient number of families in which haplotypes
could be determined, it was not possible to accurately
date this mutation.
We then tried to determine where the duplication orig-
inated. The origins of three of the families positive for
the duplication could not be traced (table 4). However,
the remaining ones are, in all but one case, compatible
with the assumption that the ancestor for this mutation
was British, because they are either of British descent or
from countries—Ireland, Portugal, and Belgium—that
have trading or other historical links with Britain. Five
of the British families are from northern England,mainly
Yorkshire, suggesting a northern British origin for the
ancestor of this mutation. The exception is a U.S. family
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Table 3
BRCA1 Exon 13–Duplication Screening in Breast and/or Ovarian Cancer Cases
COUNTRY
AND TOWN
NO. OF
POSITIVE
CASES
NO. (AGE [YEARS]) OF SCREENED CASES
Breast Cancer Ovarian Cancer
Breast and
Ovarian Cancer
Canada:
Toronto 0 24 (!45) … 5
Ireland:
Dublin 0 14 (!50) … …
United Kingdom:
London 0 59 (!35) … 2
Sutton 0 617 (!45) … …
Austria:
Vienna 0 14 (!35) 4 (!40) …
Belgium:
Gent 1 16 (!35) 1 (!35) …
Germany:
Dusseldorf 0 2 (!40) … …
Heidelberg 0 70 (!40) … …
Spain:
Barcelona 0 90 (!35) … …
Turkey:
Ankara 0 16 (!32) … …
Total 1 922 5 7
Table 4
Origin and Phenotype of the Families Carrying the BRCA1 Exon 13 Duplication
TOWN WHERE SCREENING WAS DONE NATIONALITY ORIGIN
NO. OF CASES
Breast Cancer Ovarian Cancer
Lyona (France) American Irish/Dutch 1 4
Lyona(France) American English 7 3
Lyona(France) American Unknown 7 0
Lyona(France) Portuguese Portuguese 3 0
Gent (Belgium) Belgian Unknown 2 0
Perth (Australia) Australian Unknown 4 1
Toronto (Canada) American Irish/Scottish/English/German 4 0
St. Andrews (Great Britain) British English/Polish 3 0
Leeds (Great Britain) British English 3 3
Leeds (Great Britain) British English 2 3
Leeds (Great Britain) British French/English 4 1
Leeds (Great Britain) British English 5 1
London (Great Britain) British English 1 2
Philadelphia (United States) American Dutch/German/French/English 8 3
Rochester (United States) American Norwegian/Swedish 4 0
Total 58 21
a Families reported by Puget et al. (1999a).
of Norwegian and Swedish ancestries. Another possi-
bility is that the duplication could be of Viking origin,
since all the countries mentioned above also had contact
with Vikings. However, against this possibility, no du-
plication carrier has been identified in Sweden or in Nor-
way; but the number of families screened was low in
both countries (29 and 19, respectively; table 2). Alter-
natively, this U.S. carrier may not be fully aware of all
her ancestors.
Eleven more families have been identified as carrying
the exon 13 duplication, either in different series or after
this study: two from Australia, one from New Zealand
(E. Edkins, personal communication), five from Canada
(S. Narod and C. Phelan, personal communication; N.
Carson, personal communication), and three fromGreat
Britain (A. Haworth, personal communication). In con-
clusion, the BRCA1 exon 13 duplication is most likely
a founder mutation distributed mainly in English-speak-
ing countries or in countries with historical links with
Britain. It would be strongly advisable, for laboratories
Reports 211
carrying out screening for BRCA1 mutations in these
countries, to include within their protocols the PCR-
based assay described here. This study emphasizes once
more the necessity of screening not only for mutations
in the coding sequence and splice sites but also for gene
rearrangements, when one is analyzing for the presence
of disease-causing mutations in the BRCA1 gene.
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